SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Nov 8, 2017
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Nov. 8, 2017 · CIK: 0001604191 · Accession: 0000000000-17-039640
AI Filing Summary & Sentiment
Reasoning
Letter
November 7, 2017 Johan M. (Thijs) Spoor President and Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, New York 11226 AzurRx BioPharma, Inc. Registration Statement on Form S-3 Filed November 1, 2017 File No. 333-221275Re: Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica Sudweeks
Show Raw Text
November 7, 2017
Johan M. (Thijs) Spoor
President and Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York 11226
AzurRx BioPharma, Inc.
Registration Statement on Form S-3
Filed November 1, 2017
File No. 333-221275Re:
Dear Mr. Spoor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jessica Sudweeks